280 related articles for article (PubMed ID: 18715113)
1. Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes.
Lutz AM; Willmann JK; Cochran FV; Ray P; Gambhir SS
PLoS Med; 2008 Aug; 5(8):e170. PubMed ID: 18715113
[TBL] [Abstract][Full Text] [Related]
2. Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations.
Hori SS; Gambhir SS
Sci Transl Med; 2011 Nov; 3(109):109ra116. PubMed ID: 22089452
[TBL] [Abstract][Full Text] [Related]
3. A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers.
Hori SS; Lutz AM; Paulmurugan R; Gambhir SS
Cancer Res; 2017 May; 77(10):2570-2584. PubMed ID: 28283654
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
6. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
7. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
[TBL] [Abstract][Full Text] [Related]
8. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study.
Funston G; Hamilton W; Abel G; Crosbie EJ; Rous B; Walter FM
PLoS Med; 2020 Oct; 17(10):e1003295. PubMed ID: 33112854
[TBL] [Abstract][Full Text] [Related]
10. Advances in proteomic prostate cancer biomarker discovery.
Goo YA; Goodlett DR
J Proteomics; 2010 Sep; 73(10):1839-50. PubMed ID: 20398807
[TBL] [Abstract][Full Text] [Related]
11. Beyond PSA: the next generation of prostate cancer biomarkers.
Prensner JR; Rubin MA; Wei JT; Chinnaiyan AM
Sci Transl Med; 2012 Mar; 4(127):127rv3. PubMed ID: 22461644
[TBL] [Abstract][Full Text] [Related]
12. Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.
Barnett CL; Tomlins SA; Underwood DJ; Wei JT; Morgan TM; Montie JE; Denton BT
Med Decis Making; 2017 Oct; 37(7):815-826. PubMed ID: 28363265
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results.
Gidwani K; Kekki H; Terävä J; Soukka T; Sundfeldt K; Pettersson K
Mol Aspects Med; 2020 Apr; 72():100831. PubMed ID: 31787337
[TBL] [Abstract][Full Text] [Related]
14. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
15. Secreted proteins as a fundamental source for biomarker discovery.
Stastna M; Van Eyk JE
Proteomics; 2012 Feb; 12(4-5):722-35. PubMed ID: 22247067
[TBL] [Abstract][Full Text] [Related]
16. Discovery and application of protein biomarkers for ovarian cancer.
Gagnon A; Ye B
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
[TBL] [Abstract][Full Text] [Related]
17. An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.
Mangé A; Dimitrakopoulos L; Soosaipillai A; Coopman P; Diamandis EP; Solassol J
J Proteomics; 2016 Jun; 142():114-21. PubMed ID: 27168011
[TBL] [Abstract][Full Text] [Related]
18. Proteomic approaches to tumor marker discovery.
Rai AJ; Zhang Z; Rosenzweig J; Shih IeM; Pham T; Fung ET; Sokoll LJ; Chan DW
Arch Pathol Lab Med; 2002 Dec; 126(12):1518-26. PubMed ID: 12456215
[TBL] [Abstract][Full Text] [Related]
19. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
Luo G; Liu C; Guo M; Cheng H; Lu Y; Jin K; Liu L; Long J; Xu J; Lu R; Ni Q; Yu X
Ann Surg; 2017 Apr; 265(4):800-805. PubMed ID: 28267695
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
